Huynh, E. et al. Synthetic intelligence in radiation oncology. Nat. Rev. Clin. Oncol. 17, 771–781 (2020).
De Ruysscher, D. et al. Radiotherapy toxicity. Nat. Rev. Dis. Primers 5, 13 (2019).
Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in most cancers therapy. Nat. Rev. Most cancers 4, 437–447 (2004).
Barker, H. E., Paget, J. T. E., Khan, A. A. & Harrington, Ok. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Most cancers 15, 409–425 (2015).
Forastiere, A. A. et al. Concurrent chemotherapy and radiotherapy for organ preservation in superior laryngeal most cancers. N. Engl. J. Med. 349, 2091–2098 (2003).
Paci, A. et al. Assessment of therapeutic drug monitoring of anticancer medication half 1—cytotoxics. Eur. J. Most cancers 50, 2010–2019 (2014).
Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The increasing function of prodrugs in up to date drug design and growth. Nat. Rev. Drug Discov. 17, 559–587 (2018).
Johnstone, T. C., Suntharalingam, Ok. & Lippard, S. J. The subsequent era of platinum medication: focused Pt(II) brokers, nanoparticle supply, and Pt(IV) prodrugs. Chem. Rev. 116, 3436–3486 (2016).
Klein, A. V. & Hambley, T. W. Platinum drug distribution in most cancers cells and tumors. Chem. Rev. 109, 4911–4920 (2009).
Wang, X., Wang, X., Jin, S., Muhammad, N. & Guo, Z. Stimuli-responsive therapeutic metallodrugs. Chem. Rev. 119, 1138–1192 (2019).
Fu, Q. et al. Exterior-radiation-induced native hydroxylation permits distant launch of purposeful molecules in tumors. Angew. Chem. Int. Ed. 59, 21546–21552 (2020).
Tanabe, Ok., Ishizaki, J., Ando, Y., Ito, T. & Nishimoto, S.-i Reductive activation of 5-fluorodeoxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation. Bioorg. Med. Chem. Lett. 22, 1682–1685 (2012).
Petit, M. et al. X-ray photolysis to launch ligands from caged reagents by an intramolecular antenna delicate to magnetic resonance imaging. Angew. Chem. Int. Ed. 50, 9708–9711 (2011).
Geng, J. et al. Switching on prodrugs utilizing radiotherapy. Nat. Chem. 13, 805–810 (2021).
Ding, Z. et al. Radiotherapy reduces N-oxides for prodrug activation in tumors. J. Am. Chem. Soc. 144, 9458–9464 (2022).
Guo, Z. et al. Radiotherapy-induced cleavage of quaternary ammonium teams prompts prodrugs in tumors. Angew. Chem. Int. Ed. 61, e202205014 (2022).
Le Caër, S. Water radiolysis: affect of oxide surfaces on H2 manufacturing beneath ionizing radiation. Water 3, 235–253 (2011).
Loh, Z. H. et al. Statement of the quickest chemical processes within the radiolysis of water. Science 367, 179–182 (2020).
Jiang, L. & Iwahashi, H. Present analysis on high-energy ionizing radiation for wastewater therapy and materials synthesis. Environ. Prog. Maintain. Vitality 39, 13294 (2020).
Spinks, J. W. T. & Woods, R. J. An Introduction to Radiation Chemistry (Wiley, 1990).
Fukumura, T., Akaike, S., Yoshida, Y. & Suzuki, Ok. Decomposition of an aqueous answer of [11C]Ro 15-4513: implication of hydrated electrons within the radiolysis of [11C]Ro 15-4513. Nucl. Med. Biol. 30, 389–395 (2003).
Fan, W., Yung, B., Huang, P. & Chen, X. Nanotechnology for multimodal synergistic most cancers remedy. Chem. Rev. 117, 13566–13638 (2017).
Wang, X. & Guo, Z. Concentrating on and supply of platinum-based anticancer medication. Chem. Soc. Rev. 42, 202–224 (2013).
Deng, Z. et al. A photocaged, water-oxidizing, and nucleolus-targeted Pt(IV) advanced with a definite anticancer mechanism. J. Am. Chem. Soc. 142, 7803–7812 (2020).
Wang, Z. et al. Phorbiplatin, a extremely potent Pt(IV) antitumor prodrug that may be controllably activated by pink gentle. Chem 5, 3151–3165 (2019).
Tolbatov, I., Coletti, C., Marrone, A. & Re, N. Perception into the electrochemical discount mechanism of Pt(IV) anticancer complexes. Inorg. Chem. 57, 3411–3419 (2018).
McCormick, M. C., Keijzer, Ok., Polavarapu, A., Schultz, F. A. & Baik, M.-H. Understanding intrinsically irreversible, non-nernstian, two-electron redox processes: a mixed experimental and computational examine of the electrochemical activation of platinum(IV) antitumor prodrugs. J. Am. Chem. Soc. 136, 8992–9000 (2014).
Ji, X. et al. Click on and launch: a chemical technique towards growing gasotransmitter prodrugs through the use of an intramolecular Diels–Alder response. Angew. Chem. Int. Ed. 55, 15846–15851 (2016).
Allegra, C. J. et al. Neoadjuvant 5-FU or capecitabine plus radiation with or with out oxaliplatin in rectal most cancers sufferers: a section III randomized scientific trial. J. Natl. Most cancers Inst. 107, djv248 (2015).
McKeown, S. R. Defining normoxia, physoxia and hypoxia in tumours—implications for therapy response. Br. J. Radiol. 87, 20130676 (2014).
Buxton, G. V., Greenstock, C. L., Helman, W. P. & Ross, A. B. Essential evaluate of fee constants for reactions of hydrated electrons, hydrogen atoms and hydroxyl radicals (·OH/·O–) in aqueous answer. J. Phys. Chem. Ref. Knowledge 17, 513–886 (1988).
Tippayamontri, T., Kotb, R., Paquette, B. & Sanche, L. Mobile uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal most cancers cell HCT116. Make investments. New Medication 29, 1321–1327 (2011).
Richard, S. & Martinez Marignac, V. Sensitization to oxaliplatin in HCT116 and HT29 cell strains by metformin and ribavirin and variations in response to mitochondrial glutaminase inhibition. J. Most cancers Res. Ther. 11, 336–340 (2015).
Babu, T., Sarkar, A., Karmakar, S., Schmidt, C. & Gibson, D. Multiaction Pt(IV) carbamate complexes can codeliver Pt(II) medication and amine containing bioactive molecules. Inorg. Chem. 59, 5182–5193 (2020).
Beck, A., Goetsch, L., Dumontet, C. & Corvaïa, N. Methods and challenges for the subsequent era of antibody–drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017).
Path, P. A. et al. Remedy of xenografted human carcinomas by BR96–doxorubicin immunoconjugates. Science 261, 212–215 (1993).
Han, Y. et al. Antitumor results and persistence of a novel HER2 CAR T cells directed to gastric most cancers in preclinical fashions. Am. J. Most cancers Res. 8, 106–119 (2018).
Wang, Q. et al. A bioorthogonal system reveals antitumour immune operate of pyroptosis. Nature 579, 421–426 (2020).
Xu, Z. et al. Nanoscale metallic–natural framework with an X-ray triggerable prodrug for synergistic radiotherapy and chemotherapy. J. Am. Chem. Soc. 145, 18698–18704 (2023).
